There's a one-liner item that BPotter cut their PAR SP to $0.47....

There's a one-liner item that BPotter cut their PAR SP to $0.47. Take 30% off that and you may have what BP think may be a CR price that they can get in the action on. Just guessing. Clearly, they can't leave open their previous SP estimate that was above the Nov exercise on options.

I remain unconvinced that PAR have a lock on 2x2 dosage.
However, i also think that FDA will provide clarity this time round as to what they really want, and whatever PAR board and management think, that clarity will lead to a response that delivers focus on getting the numbers done. It will also serve to define a TGA application with an end date of mid next year.

If FDA ask for something onerous, then PAR need to look for a suitor. Their 51C person needs to make a pitch to CSL to come on board with a capital injection on similar terms to what BP would offer, but with the imprimatur of everybody else hands-off.
Otherwise PAR need to get an ADR type 2 in the US at a cost of around $7m.
There is no prospect of a SP take-off without a favourable FDA outcome or a capital injection or a bigger investor marketplace.
IMO. DYOR.
GLTAH